VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
STLN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
STLNStarling Oncology, Inc.
$3.40$362M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. STLN
  4. Financial Ratios

Starling Oncology, Inc. (STLN) Financial Ratios

Latest Ratios: P/E Ratio -100.3x · EV/EBITDA N/A · ROE N/A. (2019–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

STLN Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Market Cap$340M$329M$23M$150M$133M$646M$638M—
Enterprise Value$410M$399M$97M$237M$227M$532M$644M—
P/E Ratio →-100.30———————
P/S Ratio0.550.650.060.460.533.183.40—
P/B Ratio——6.462.641.086.2022.72—
P/FCF12.66———————
P/OCF——————1256.83—

P/E links to full P/E history page with 30-year chart

STLN EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
EV / Revenue—0.790.250.730.902.623.44—
EV / EBITDA————————
EV / EBIT————————
EV / FCF————————

STLN Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Gross Margin15.2%15.2%13.7%18.4%20.6%20.1%19.7%19.3%
Operating Margin-7.2%-7.2%-15.3%-23.8%-32.5%-22.6%-4.4%-1.7%
Net Profit Margin-12.1%-12.1%-16.4%-25.6%0.1%-5.4%-7.6%-2.6%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
ROE——-213.4%-92.2%0.1%-16.5%-40.7%-9.5%
ROA-36.8%-36.8%-33.9%-35.3%0.1%-8.1%-22.9%-6.8%
ROIC-49.7%-49.7%-40.9%-32.0%-59.3%-285.7%-16.7%-5.0%
ROCE-38.5%-38.5%-40.8%-37.9%-40.4%-43.5%-19.7%-5.8%

STLN Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Debt / Equity——34.312.100.880.000.42—
Debt / EBITDA————————
Net Debt / Equity——20.471.510.76-1.100.21-0.06
Net Debt / EBITDA———————-8.23
Debt / FCF———————-1.01
Interest Coverage-4.39-4.39-7.63-8.88-17.64-141.82-41.69-780.67

STLN Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Current Ratio1.591.592.154.124.395.171.041.60
Quick Ratio1.351.351.963.734.084.950.891.32
Cash Ratio0.470.470.952.382.483.840.210.18
Asset Turnover—3.052.281.550.961.002.852.61
Inventory Turnover25.2625.2633.8119.3521.6425.1934.6032.26
Days Sales Outstanding—43.0745.1748.3158.4538.2033.5934.61

STLN Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Dividend Yield————————
Payout Ratio————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Earnings Yield————————
FCF Yield7.9%———————
Buyback Yield0.0%0.0%0.0%0.7%6.8%0.0%0.0%—
Total Shareholder Yield0.0%0.0%0.0%0.7%6.8%0.0%0.0%—
Shares Outstanding—$92M$75M$74M$81M$66M$59M$64M

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Negative equity and thin margins

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Margins Recover but Remain Thin

According to quarterly financials, TOI's operating margin improved from -19.0% in 2024Q1 to -2.9% in 2026Q2, while gross margin hovered near 14-16%, indicating persistent cost pressure despite revenue growth.

The operating margin trend shows a clear inflection: losses narrowed from -$18.0M in 2024Q1 to -$4.6M in 2026Q2, a 74% reduction, per the income statement. However, gross margin remains thin and volatile, fluctuating between 12.6% and 16.5% over the period, suggesting limited pricing power in a competitive oncology services market. Net margin is still deeply negative at -6.1% in 2026Q2, implying that even with operating leverage, the company has not yet reached breakeven, and the path to profitability may be longer than the revenue acceleration suggests.

Capital Returns Deeply Negative

Based on reported figures, ROIC deteriorated from -10.0% in 2024Q1 to -41.0% in 2026Q2, while ROE turned sharply negative as equity eroded to -$24.9M, indicating severe value destruction on invested capital.

ROIC has worsened dramatically, from -10.0% in 2024Q1 to -41.0% in 2026Q2, even as revenue grows, because the capital base is shrinking while losses persist. ROE is not calculable in recent quarters due to negative equity, but when reported, it was -138.2% in 2024Q4, reflecting the impact of cumulative losses exceeding capital. The negative equity position suggests that the company is not compounding returns but rather consuming its capital base, and any recovery in ROIC will require both margin expansion and a stabilized equity base.

Working Capital Efficiency Improves

Per the latest quarterly data, TOI's cash conversion cycle shortened from 43 days in 2024Q1 to 18 days in 2026Q1, driven by faster receivables collection (DSO down from 49 to 36 days) and extended payables.

The cash conversion cycle has compressed significantly, from 43 days in 2024Q1 to 18 days in 2026Q1, as DSO fell from 49 to 36 days and DPO rose from 20 to 33 days, indicating improved working capital management. This efficiency gain contributed to the positive operating cash flow in 2026Q2, but the improvement may be partly due to revenue growth and timing, not structural change. Asset turnover also improved from 0.46 to 0.93 over the period, suggesting better revenue generation per dollar of assets, though this is partly a function of a shrinking asset base.

Debt Reduced but Equity Negative

As reported in balance sheet data, total debt fell from $119.8M in 2024Q1 to $24.6M in 2026Q2, but equity turned negative at -$24.9M, leaving the company with a strained capital structure despite lower leverage.

The debt reduction is substantial, with total debt down 79% over ten quarters, but the equity position has deteriorated to -$24.9M, indicating that the paydown was funded by asset liquidation and accumulated losses. Interest coverage remains negative, at -2.48 in 2026Q2, meaning operating income cannot cover interest expenses, though the absolute debt level is now lower. The negative equity suggests that the company is technically insolvent on a book basis, and any future financing may be constrained, though the shift to short-term debt (current ratio down to 1.36) warrants monitoring.

Liquidity Buffer Thins Rapidly

Based on quarterly ratios, TOI's current ratio fell from 3.08 in 2024Q1 to 1.36 in 2026Q2, while cash remained around $41M, indicating a shrinking liquidity cushion relative to short-term obligations.

The current ratio has more than halved over ten quarters, from 3.08 to 1.36, even though cash increased slightly to $41.1M, because current liabilities have grown faster, likely due to the shift to short-term debt. The quick ratio of 1.15 in 2026Q2 suggests that even without inventory, the company can cover near-term obligations, but the trend is concerning. Under a severe stress scenario, such as a revenue shortfall or margin compression, the liquidity position could become strained, especially given the negative equity and reliance on working capital swings for cash flow.

P/S Ratio Misleads on Value

The most commonly misapplied ratio for TOI is the price-to-sales multiple, which at 10.51 appears rich but obscures the fact that the company is unprofitable and has negative equity, making earnings-based or EV-based metrics more relevant.

With a P/S of 10.51, TOI trades at a premium to its revenue, but this multiple is misleading because the company has negative net income and negative equity, so the market is pricing in future profitability that has not yet materialized. EV/EBITDA is not meaningful because EBITDA is negative, and P/E is negative, so investors should focus on the trajectory of operating margins and cash flow generation rather than revenue multiples. A more appropriate metric would be EV/Revenue adjusted for the company's cash burn rate, or a forward-looking margin-based valuation, to assess whether the current market cap of roughly $1.7B (implied by P/S) is justified by the path to breakeven.

Download Financial Ratios Data

Includes 30+ ratios · 7 years · Updated daily

Consensus & Technical Research Suite
Open STLN Terminal

STLN Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

STLN — Frequently Asked Questions

Quick answers to the most common questions about buying STLN stock.

What is Starling Oncology, Inc.'s P/E ratio?

Starling Oncology, Inc.'s current P/E ratio is -100.3x. This places it at the 50th percentile of its historical range.

Is STLN stock overvalued?

Based on historical data, Starling Oncology, Inc. is trading at a P/E of -100.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Starling Oncology, Inc.'s profit margins?

Starling Oncology, Inc. has 15.2% gross margin and -7.2% operating margin.